Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orbitaximod
- Development stage
- Unknown
- Lead developer
- Shenzhen Zhenxing Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Orbitaximod (SM-1) is an orally bioavailable, small-molecule Toll-like receptor 7 (TLR7) agonist developed by Shenzhen Zhenxing Pharmaceutical Technology. It is specifically formulated as enteric micro-pellet capsules to optimize gastrointestinal delivery and minimize systemic toxicity. As a TLR7 agonist, orbitaximod acts as an immunomodulator that stimulates the innate immune system, particularly activating antigen-presenting cells such as dendritic cells and macrophages. This activation leads to the secretion of pro-inflammatory cytokines and the subsequent induction of a robust T-cell-mediated antitumor immune response. The drug is currently being investigated in Phase 1 clinical trials for the treatment of advanced solid tumors and relapsed or refractory lymphomas, where it aims to overcome immune evasion in the tumor microenvironment.
- Other names
- orbitaximod fumarate
02
Targets
TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on orbitaximod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orbitaximod.